Clinical trial shows that adding Bevacizumab to targeted drug and chemotherapy produces striking activity against HER2-positive Metastatic Gastroesophageal Adenocarcinoma

Posted date

RESEARCH SUMMARY

Clinical trial shows that adding Bevacizumab to targeted drug and chemotherapy produces striking activity against HER2-positive Metastatic Gastroesophageal Adenocarcinoma

Study Title: Long-term results and ctDNA correlatives for CAPOX BETR: A multi-center phase II trial of capecitabine, oxaliplatin, bevacizumab and trastuzumab for previously untreated HER2 positive metastatic gastroesophageal adenocarcinoma

Publication: AACR Poster Session, Presentation No. CT155; Poster Board No: 17

Dana-Farber Cancer Institute author: Harshabad Singh, MBBS, MD

Summary: 

Addition of the drug bevacizumab to chemotherapy and a HER2-targeted agent, herceptin, showed striking activity in a clinical trial involving patients with HER2-positive metastatic gastroesophageal adenocarcinoma – comparable to the effect of current standard therapy, which includes an immunotherapy agent targeting the PD-1 protein on T cells. In the trial, 37 patients with previously untreated cancers received standard chemotherapy (capecitabine and oxaliplatin) and trastuzumab (a HER2-targeting agent), followed by bevacizumab, an anti-angiogenic drug that blocks blood vessel growth to tumors. Eighty-one percent of the participants responded to the treatment. At a median follow-up of 23.2 months, all the patients were alive, and the progression-free survival (PFS) was 14 months. That compares with a response rate of 74% for the current standard therapy, which consists of chemotherapy, trastuzumab, and the immunotherapy drug pembrolizumab. The six-month PFS for standard therapy is 70.3%, compared to 77% for the regimen including bevacizumab. The findings may lay the groundwork for a clinical trial of bevacizumab in combination with standard therapy, investigators say.

Impact:

For patients with HER2-positive metastatic gastroesophageal adenocarcinoma, a clinical trial found that a combination of the anti-angiogenic drug bevacizumab, chemotherapy, and a HER2-targeted agent had impressive clinical activity. A median of nearly two years after the trial, all 37 participants were alive. The findings may lay the groundwork for a trial of bevacizumab and standard therapy, which includes an immunotherapy drug. 

Funding: 

The study was funded by Genentech. The analysis of circulating tumor DNA was done in collaboration with Predicine, Inc.


News Category
Gastrointestinal Cancer
Related Doctors and Researchers

Media Contacts

If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email media@dfci.harvard.edu.

The Media Team cannot respond to patient inquiries. For more information, please see Contact Us.